Valneva (NASDAQ:VALN) Trading Down 4.6% – Should You Sell?

Valneva SE Sponsored ADR (NASDAQ:VALN) traded down 4.6% on Tuesday . The stock traded as low as $8.07 and last traded at $8.3890. 29,606 shares were traded during trading, a decline of 51% from the average session volume of 60,637 shares. The stock had previously closed at $8.79.

Analysts Set New Price Targets

Several analysts recently commented on VALN shares. Guggenheim cut their price objective on Valneva from $14.00 to $13.00 and set a “buy” rating for the company in a report on Monday, September 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Valneva in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut shares of Valneva from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Valneva Stock Down 4.9%

The company has a quick ratio of 1.36, a current ratio of 1.78 and a debt-to-equity ratio of 0.72. The company has a fifty day simple moving average of $8.90 and a 200-day simple moving average of $8.63. The firm has a market cap of $719.45 million, a P/E ratio of -5.82 and a beta of 1.83.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Thursday, November 20th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.31). The company had revenue of $34.01 million for the quarter, compared to analysts’ expectations of $48.85 million. Valneva had a negative net margin of 57.81% and a negative return on equity of 59.44%. On average, equities analysts anticipate that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current year.

Institutional Trading of Valneva

Several institutional investors and hedge funds have recently modified their holdings of VALN. Frazier Life Sciences Management L.P. bought a new stake in shares of Valneva during the 2nd quarter valued at $8,240,000. Marex Group plc purchased a new position in shares of Valneva in the second quarter valued at about $64,000. JPMorgan Chase & Co. bought a new position in shares of Valneva in the third quarter worth about $124,000. Finally, VSM Wealth Advisory LLC grew its position in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after purchasing an additional 5,000 shares in the last quarter. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.